Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study

Hae-Jin Suh Oh1†, Ángeles Flórez Menéndez1†, Víctor Sacristán Santos2, Ángeles Rodríguez Martínez3, Francisca Fernández Ribeiro4, Lucía Vilanova-Trillo1, Manuel Constenla Figueiras3 and Manuel Pereiro Ferreiros5

Abstract
Background: The aim of the study was to assess health-related quality of life (HRQOL) in outpatients receiving anti-cancer treatment.

Methods: Observational, cross-sectional, single-center study that assessed HRQOL in cancer patients receiving antineoplastic treatment.

Results: A total of 184 patients were included in the study; the median total FACT-G score was 66 ± 12.9; the scores for the physical well-being, social/family well-being, emotional well-being and functional well-being domains were 17.8 ± 4.8, 19.1 ± 4.4, 14.8 ± 3.8 and 14.3 ± 4.7 respectively. Patients with adverse events had poorer HRQOL compared to those without them (FACT-G score 62.2 vs. 67.3; p < 0.05). In the multivariate analysis the variables associated with poorer HRQOL in the form of a gradient were tumor stage and performance status (ECOG); female sex was also associated with poorer HRQOL.

Conclusion: In our study, the neoplastic disease and anti-cancer treatment toxicities had an impact on HRQOL. Patients had poorer scores in the functional well-being domain and higher ones in the social/family well-being domain. Variables associated with worse HRQOL were tumor stage, performance status (ECOG) and female sex.

Keywords: Cancer, Cutaneous adverse events, Targeted therapies, Patient-reported outcomes, FACT-G, Quality of life

Background
In general, health-related quality of life (HRQOL) encompasses the subjective perceptions of the positive and negative aspects of disease, including physical, emotional, social and cognitive functions and, in particular, disease symptoms and treatment side effects. In last decades, HRQOL has increasingly become a major focus in cancer studies and the information on this particular topic is increasingly required by medical agencies in the context of approval of new treatment options [1–3]

A patient-reported outcome (PRO) is a measurement of any aspect of a patient’s health status that is retrieved directly from the patient. The information captured by a PRO instrument can provide first-hand evidence of the benefit or detriment of health status from the patient’s perspective and helps to identify specific issues that may modify treatment decisions and provide guidance for determining an appropriate and personalized care [4–6].
In clinical research, the Functional Assessment of Cancer Therapy-General (FACT-G) has been validated and one of the most commonly used PRO instruments to assess HRQOL in cancer patients. It can be used to objectively quantify issues in domains that are not routinely screened along the treatment in cancer patients. Early recognition of HRQOL issues in specific domains of FACT-G that are not consistently examined in routine care helps to improve patient satisfaction, increase survival rates, reduce hospitalizations, and decrease costs to the healthcare system [7–9].

Although PRO instruments are usually incorporated in clinical trials, there is not extensive data regarding overall HRQOL in daily clinical practice. Therefore, the main objective of the current study was to assess HRQOL in outpatients receiving anti-cancer treatment in daily clinical practice using the Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire. Secondary objectives were to evaluate the impact of adverse events (AEs) and to explore possible predictors of quality of life.

**Methods**

**Study design**

Cross-sectional, observational study conducted in a single centre between April and December 2018.

**Study population and recruitment**

A total consecutive sampling of patients meeting eligibility criteria (age equal to or greater than 18 years old, any solid tumor under active antineoplastic treatment, which include conventional chemotherapy, targeted therapy and immunotherapy) was performed at the Medical Oncology Service of the University Hospital Center (CHU) Pontevedra, Spain. Patients receiving radiotherapy at the time of initial evaluation and those not able to answer PRO questionnaires were excluded.

Physicians and nurses at the Medical Oncology Service Day Hospital and at the hospital dispensing office of cancer drugs carried out recruitment of patients.

**Study procedures and variables**

Informed consent was obtained from study participants before performing any study procedure. A medical oncologist evaluated patients that met the eligibility criteria. Patients that developed cutaneous adverse events (CAEs) were additionally evaluated by a dermatologist. Detailed history and examination were performed to confirm CAEs and classify them according to usual clinical practice.

To assess patient overall HRQOL, the FACT-G questionnaire was used. The FACT-G comprises an overall score (scale range 0–108, higher score reflects better quality of life) and 4 subscale scores: physical well-being (PWB, range 0–28), social/family well-being (SFWB, range 0–28), emotional well-being (EWB, range 0–24), and functional well-being (FWB, range 0–28). The necessary license for the use of the FACT-G questionnaire was obtained. A prior Spanish version of FACT-G showed good reliability and validity to be used as a HRQOL tool among Spanish-speaking patients [10, 11]. Patients completed paper FACT-G questionnaires.

The ECOG (Eastern Cooperative Oncology Group) Scale of Performance Status (PS) was used to quantify the functional status of patients [12]. Tumor stage was determined using the American Joint Committee on Cancer (AJCC) TNM classification [13].

Data on demographic and clinical characteristics were collected. This was done through an interview with the participants, as well as with the review of their medical history. CTCAE (version 4.03) was used to determine the severity of AEs [14].

Targeted therapies were considered all those that act against specific molecular targets, monoclonal antibodies and immunotherapies. All classic antineoplastic drugs were considered non-targeted therapies.

**Statistical analysis**

Stata V12.0 statistical software (Stata Corporation, College Station, TX, USA) was used for statistical analysis.

**Descriptive analysis**

The clinical and sociodemographic characteristics of the sample were described using measures of central tendency and dispersion in the case of quantitative variables, as well as frequency tables and distribution of percentages in the case of qualitative variables.

Patients with different levels of HRQOL were compared using statistical hypothesis testing (Student t-test, Mann–Whitney U test). For all tests the level of significance was set to $p=0.05$ (level adjusted according to Bonferroni procedure when necessary). Chi square was performed in case of categorical data with Fisher’s exact test when needed.

General quality of life, measured by the FACT-G questionnaire, was examined as well as its association with severity and number of adverse events, general condition of the patient, type of tumor, tumor stage, type of treatment and number of cycles received by the patient. To achieve this, contrast tests of media differences were used for continuous variables of normal distribution (ANOVA) and non-normal distribution (Kruskal–Wallis).

Possible HRQOL predictors were studied using bivariate and multivariate linear regression models. For the inclusion of the variables in the models, the results of the bivariate analysis (variables with $p$ value < 0.250), the theoretical sense and the sample size were taken into
account. The comparison between models was made using the Akaike information criterion (AIC) and Bayesian information criterion (BIC) methods.

Effects of possible confounding factors (type of tumor, preventive treatment, type of antineoplastic treatment, general condition, age and sex) were controlled using multivariate analysis.

**Results**

**Characteristics of the study population**

A total of 201 patients were eligible for the study, and 17 declined to participate. Thus, 184 patients were included in the study: 103 (56%) women and 81 (44%) men; mean age was 60.5 ± 11.8 and the most frequent tumors were gastrointestinal cancer (38%) followed by breast (25.5%) and lung (15.8%) cancer; 103 (56%) patients received targeted therapy and 81 (44%) conventional chemotherapy. The majority of patients presented with tumor stage IV (77.7%) and most of the patients included in our study were symptomatic but completely ambulatory (77.2%); 126 (68.4%) patients had previous medical conditions (hypertension, diabetes or dyslipemia (72.2%), depression and anxiety (13.4%), hypothyroidism (11.2%), others (3.2%)). Demographic and clinical characteristics of study population are summarized in Table 1.

**Adverse events**

In our study, 142 (77.2%) patients developed AEs and 42 (22.8%) did not have any AE; 114 patients (61.9%) developed cutaneous AEs (CAEs), 73 patients (39.6%) presented non cutaneous AEs (NCAEs); total number of AEs was 260 (177 CAEs and 83 NCAEs); 126 (68.5%) patients had one AE and 58 (31.5%) had two or more concomitant AEs; most patients had grade 1 or 2 AEs (69.2% and 25.8% respectively). Characteristics of AEs are summarized in Table 2.

**Quality of life indices**

All patients included in the study (N = 184) answered the FACT-G questionnaire, with an average score of 66 ± 12.9. The scores for the domains were as follows: 17.8 ± 4.8 in physical well-being (PWB); 19.1 ± 4.4 social/family well-being (SFWB); 14.8 ± 3.8 in emotional well-being (EWB); 14.3 ± 4.7 in functional well-being (FWB) (Fig. 1).

Patients that presented AEs had significantly poorer HRQOL compared to patients that did not present any AE (total FACT-G score 62.2 vs. 67.3; p = 0.03). Regarding domain data, there were no differences in SFWB and FWB, but patients with AEs presented poorer HRQOL in PWB and EMB domains (Table 3).

**Quality of life predictors**

General HRQOL, measured by the FACT-G questionnaire, was not associated to the type of tumor, type of treatment, duration of treatment, or the number of previous treatment lines received. On the contrary, an association was found between HRQOL and tumor stage (p = 0.02), the general condition measured by the ECOG PS (p = 0.0001), and the number and severity of AEs (p = 0.03 and p = 0.01, respectively).

Bivariate and multivariate analysis results showed that variables associated with HRQOL were tumor stage, general condition measured by the ECOG performance

### Table 1: Demographic and clinical characteristics

| Variable                          | Total n = 184 |
|-----------------------------------|---------------|
| Gender, n (%)                     |               |
| Male                              | 81 (44.0)     |
| Female                            | 103 (56.0)    |
| Age at diagnosis, years           |               |
| Mean (SD)                         | 60.5 (11.8)   |
| Median (IQR)                      | 63.2 (51.4–70.3) |
| Tumor type, n (%)                 |               |
| Gastrointestinal                  | 70 (38.0)     |
| Breast                            | 47 (25.5)     |
| Lung                              | 29 (15.8)     |
| Urological/renal                  | 18 (9.8)      |
| Gynecologic                       | 9 (4.9)       |
| Other                             | 11 (6.0)      |
| Tumor stage, n (%)                |               |
| Stage II                          | 15 (8.1)      |
| Stage III                         | 26 (14.1)     |
| Stage IV                          | 143 (77.7)    |
| Type of treatment, n (%)          |               |
| Conventional chemotherapy         | 81 (44.0)     |
| Targeted therapy                  | 103 (56.0)    |
| Previous lines of treatment, n    |               |
| Mean (SD)                         | 1.44 (0.96)   |
| Median (IQR)                      | 1 (1–2)       |
| Treatment duration, months        |               |
| Mean (SD)                         | 6.8 (6.8)     |
| Median (IQR)                      | 4 (2–8.5)     |
| Previous medical conditions       |               |
| No                                | 58 (31.5)     |
| Yes                               | 126 (68.4)    |
| ECOG Performance Status           |               |
| 0 (Asymptomatic)                  | 9 (4.9)       |
| 1 (Symptomatic, but completely ambulatory) | 142 (77.2) |
| 2 (Symptomatic, < 50% of time in bed) | 30 (16.3) |
| 3 (Symptomatic, > 50% of time in bed) | 3 (1.6)     |

SD, standard deviation; IQR, interquartile range
status and female sex. The following variables were not associated with HRQOL: appearance of CAEs, type of treatment, type of tumor, duration of treatment, number of previous lines of treatment, presence of concomitant disorders and age (Table 4.)

**Discussion**

Quality of life assessment in cancer patients has become an important factor to consider in a scenario in which successful treatment is measured not only in terms of overall survival or progression free survival, but also in terms of HRQOL maintenance or improvement. Multiple PRO instruments are usually incorporated in clinical trials or clinical research, they are either cancer specific, treatment specific or symptom specific, but there is not extensive data regarding overall HRQOL in daily clinical practice.

The purpose of our study was to evaluate general quality of life in outpatients receiving anti-cancer therapy by means of FACT-G, a well-known PRO instrument in the context of cancer research. This questionnaire specifically developed for cancer patients has gone through many validation studies and is one of the most commonly used tools to assess HRQOL in cancer patients and survivors [7–9]. A previous Spanish version of FACT-G demonstrated good reliability and validity to be used as a HRQOL instrument among Spanish-speaking patients [10, 11].

In our study, the median total and subdomain FACT-G scores were similar to the results reported by Abu Sharour et al. (total FACT-G score 65.79 + 12.03; PWB 16.94 + 7.32; SFWB 18.6 + 4.59; EWB 14.83 + 5.35; FWB 12.36 + 7.03). They evaluated quality of life in cancer patients during their treatment phase, and as in our study, the highest scores were obtained in the SFWB domain and the lowest in the FWB and EWB domains[15].

Jacob et al. also evaluated HRQOL among cancer patients with advanced disease and reported a total FACT-G score of 62.4 + 10.0, with the lowest score in the FWB domain as well (9.3 + 3.8); in their study the most important predictor of lower quality of life was financial difficulty [16].

Regarding AEs, in our study patients that developed AEs had significantly poorer quality of life compared to patients without AEs (total FACT-G score 62.2 vs 67.3; p = 0.03), and differences were also statistically significant in PWB and EWB domains. Likewise, other studies that evaluated the impact of different AEs on quality of life found that PWB and EWB domains had the greatest negative impact [17–20].

Although we cannot make direct comparisons with other studies due to the different PRO instruments used to evaluate HRQOL, the use of antineoplastic agents is usually associated to adverse events and these are known to have an impact on patients’ HRQOL [21–23].

In our study, the most frequent AEs were asthenia or cancer-related fatigue, pruritus, xerosis, palmar-plantar erythrodysestesia and alopecia. Cancer-related fatigue can be present in 48–75% of cancer patients and it is one of the most frequent symptoms reported by these patients and has a well known impact on HRQOL [23, 24].

Pruritus and xerosis can be major AEs associated with EGFR inhibitors and in a study carried out by Clabbers et al. pruritus and xerosis were reported by the patients as the most impactful AEs[25].

Palmar-plantar erythrodysestesia or hand foot syndrome may appear with various molecules and can affect up to 50% of patients receiving capecitabine [26].

A study performed by Urakawa et al. concluded that this AE had a stronger impact on HRQOL compared to other skin toxicities of chemotherapy [27].

### Table 2 Adverse Events (AEs)

| Variable | Total (%) |
|----------|-----------|
| Patients that presented AEs, n (%) | 142 (77.2) |
| No | 42 (22.8) |
| Total number of AEs | 260 |
| Type of AEs, n (%) |  |
| Asthenia | 35 (13.5) |
| Pruritus | 29 (11.2) |
| Xerosis | 24 (9.2) |
| Palmar-plantar erythrodysesthesia (PPE) | 24 (9.2) |
| Alopecia | 21 (8.0) |
| Neurotoxicity | 20 (7.7) |
| Papulopustular rash | 17 (6.5) |
| Gastrointestinal toxicity | 16 (6.2) |
| Ungual apparatus alterations | 13 (5.0) |
| Pigmentary changes | 13 (5.0) |
| Others* | 48 (18.5) |
| Number of AEs per patient, n(%) |  |
| Patients with one AE | 126 (68.5) |
| Patients with two or more AEs | 58 (31.5) |
| Severity of AEs, n (%) |  |
| Grade 1 | 180 (69.2) |
| Grade 2 | 67 (25.8) |
| Grade 3 | 13 (5.0) |
| Grade 4 | – |
| Treatment interruption due to AEs | 20 (10.9) |
| Yes |  |
| No | 164 (89.1) |

* Others: photosensitivity, arthromyalgia, hematological toxicity, mucositis, dysgeusia, headache, folliculitis, trichomegaly, eyelid edema, purpura, other erythematous cutaneous reactions
Finally, alopecia can be related to conventional chemotherapy, targeted therapy or hormonotherapy and has a clearly negative emotional effect that was reported by Freites-Martinez et al. [28]. In our study we also evaluated possible determinants of HRQOL and found that general quality of life, measured by FACT-G, was statistically associated with tumor stage, performance status (ECOG) and the number and severity of AEs. On the contrary, it was not associated with the type of tumor, type of treatment or duration and number of previous treatment lines received. In the multivariate analysis the variables associated with poorer quality of life in the form of a gradient were tumor stage and performance status (ECOG); female sex was also associated with poorer quality of life.

Our results highlight that despite the great advances made in tumor biology knowledge, development of multiple new drugs and improvement in supportive care, these factors remain as quality of life determinants in daily clinical practice. Cella et al. developed and validated the FACT-G questionnaire and proved that the scale was able to discriminate patients on the basis of stage of the disease and performance status [29]. They also found that FACT-G sensitivity to stage was observed not only in the total score but also in the PWB and FWB domains. Considering the fact that in our study most patients had an advanced disease (77.7% stage IV) and one of the most affected domain was the PWB domain, this data is consistent with that reported by Cella et al.

Edianto et al. assessed HRQOL in gynecologic cancer patients using FACT-G in an observational cross-sectional study. They did not find differences between treatment modalities, treatment duration and disease stage based on the total score of FACT-G [30]. In their study most patients included had an early stage of the disease (57% stage I-II; 43% stage III; no patients with stage IV), in contrast to our study where most of the patients had a stage IV of the disease (77.7%), which could explain the differences regarding disease stage.

We also found that female sex was associated with a lower HRQOL. Some authors (Lee et al., Barbu et al., Andreis et al.) also reported a poorer HRQOL associated

---

**Table 3** FACT-G scores according to the presence of AEs

| FACT scores | Patients with AEs (N = 142) | Patients without AEs (N = 42) | p value |
|-------------|------------------------------|------------------------------|---------|
| FACT-G total (0–108) Mean (95% CI) | 62.2 (60.0–64.3) | 67.3 (63.7–70.8) | 0.03 |
| PWB (0–28) Mean (95% CI) | 16.2 (15.4–17.1) | 19.5 (18.1–20.7) | < 0.01 |
| SFWB (0–28) Mean (95% CI) | 19.1 (18.5–19.7) | 18.3 (17.0–19.5) | 0.21 |
| EWB (0–24) Mean (95% CI) | 13.1 (12.4–13.7) | 15.9 (14.8–16.9) | < 0.01 |
| FWB (0–28) Mean (95% CI) | 13.7 (12.9–14.5) | 13.7 (12.3–15.0) | 0.94 |

---

**Fig. 1** Total FACT-G score and Physical Well Being, Social Family Well Being, Emotional Well Being and Functional Well Being domain subscale scores in outpatients receiving anti-cancer treatment
To female sex, while others did not confirm the same effect (Charles et al., Urakawa et al.) [19, 27, 31–34].

Contradictory data have also been observed in other non-oncological diseases and this could be due to different symptoms perception, associated comorbidities, degree of disease acceptance or each individual characteristics [34, 35].

Our results highlight the importance of measuring HRQOL in daily clinical practice in outpatients receiving anti-cancer treatment. In our study the lowest scores were obtained in the FWB and EWB domains; these results emphasize the fact that in our study population there could be unmet needs in those particular areas.

Another finding of our study is that there are preventive measures for some of the most frequent AEs, which can clearly have an impact in HRQOL. These results have led us to reinforce joint work with oncology nursing in ambulatory care and pay more attention to provide emotional support and information about preventive measures related to AEs.

Given that we did not have data on the quality of life of these patients, the results of the present study have provided us with useful information to know in which areas it is necessary to put more emphasis and thus, together

Table 4 Quality of life determinants in bivariate and multivariate analysis

| Variables                      | Bivariate β [95% CI] (p value) | Multivariate β [IC 95%] (p value) |
|--------------------------------|---------------------------------|-----------------------------------|
| Cutaneous adverse events       | −1.88 [−5.73; 1.98] (0.339)     |                                   |
| Type of treatment              |                                 |                                   |
| Conventional chemotherapy      |                                 |                                   |
| Targeted therapy               | −0.98 [−4.76; 2.80] (0.610)     |                                   |
| Type of tumor                  |                                 |                                   |
| Breast                         | 1                               |                                   |
| Digestive                      | 1.63 [−3.20; 6.47] (0.505)      |                                   |
| Lung                           | −2.14 [−8.19; 3.91] (0.485)     |                                   |
| Gynecological                  | −2.21 [−11.5; 7.11] (0.640)     |                                   |
| Urological                      | 0.18 [−6.92; 7.28] (0.961)      |                                   |
| Other                          | 0.60 [−7.98; 9.18] (0.891)      |                                   |
| Tumor stage                    |                                 |                                   |
| 2                              |                                 |                                   |
| 3                              | −11.4 [−19.4; −3.42] (0.005)    | −10.18 [−17.38; 2.99] (0.006)     |
| 4                              | −12.0 [−18.7; −5.29] (0.001)    | −11.59 [−17.66; −5.52] (< 0.0001) |
| Number of treatment cycles     |                                 |                                   |
| 1–5                            | 5.75 [0.92; 10.58] (0.020)      |                                   |
| 6–10                           | 4.82 [−1.95; 11.60] (0.162)     |                                   |
| 11–15                          | 1.11 [−7.66; 9.88] (0.804)      |                                   |
| 16–20                          | 2.55 [−3.89; 9.00] (0.436)      |                                   |
| More than 20                   |                                 |                                   |
| Performance status (ECOG)      |                                 |                                   |
| 0                              | −14.37 [−22.41; −6.32] (0.001) | −14.63 [−22.26; −7.01] (< 0.0001) |
| 1                              | −22.47 [−31.36; −13.57] (< 0.0001) | −21.28 [−29.72; 12.85] (< 0.0001) |
| 2                              | −36.0 [−51.60; −20.40] (< 0.0001) | −34.11 [−48.91; −19.31] (< 0.0001) |
| 3                              | −36.0 [−51.60; −20.40] (< 0.0001) | −34.11 [−48.91; −19.31] (< 0.0001) |
| Performance status (ECOG)      |                                 |                                   |
| 0                              |                                 |                                   |
| 1                              | −14.37 [−22.41; −6.32] (0.001) | −14.63 [−22.26; −7.01] (< 0.0001) |
| 2                              | −22.47 [−31.36; −13.57] (< 0.0001) | −21.28 [−29.72; 12.85] (< 0.0001) |
| 3                              | −36.0 [−51.60; −20.40] (< 0.0001) | −34.11 [−48.91; −19.31] (< 0.0001) |
| Previous treatment lines       |                                 |                                   |
| 1                              | −0.76 [−6.54; 5.03] (0.796)     |                                   |
| 2                              | −6.96 [−15.07; 1.15] (0.092)    |                                   |
| Concomitant disorders           | −2.35 [−6.38; 1.68] (0.252)     |                                   |
| Age                            | −0.05 [−0.21; 0.10] (0.502)     |                                   |
| Female sex                     | −4.62 [−8.34; −0.89] (0.015)    | −4.01 [−7.40; −0.63] (0.020)      |
with nursing, develop recommendations for patients regarding the prevention and management of possible adverse events.

Limitations
A limitation of the present study is that it had an observational cross-sectional design and was limited to patients from only one hospital in Pontevedra, Spain. Bias generated by using data from a single institution is also related to bias from geographical location, institutional culture, and referral patterns. Due to the cross-sectional design, the evaluation of the HRQOL was conducted only at a particular time in the patient’s life, but no repeated observations or follow-up were performed. These features could have affected the results and may limit its generalizability.

Conclusion
Our results highlight the fact that HRQOL is a subjective and multi-dimensional concept that can be influenced not only by the disease and its treatment, but also by psychological and social aspects as well as individual coping strategies. We must take into account all these factors and adapt to the specific needs of our patients. Routinely use of PRO instruments in daily clinical practice can be useful in decision making, improve patient-physician relationship, help to detect unmet needs in our patients and improve health care delivery through a comprehensive patient-centered approach.

Acknowledgements
Writing and editorial assistance was provided by Content Ed Net (Madrid, Spain).

Authors’ contributions
All authors contributed extensively to the work presented in this paper. All authors have contributed significantly to the conception, design, or acquisition of data, or analysis and interpretation of data. All authors have participated in drafting, reviewing, and/or revising the manuscript and have approved its submission. All authors read and approved the final manuscript.

Funding
This study was developed as part of an initiative of the research team. Researchers did not receive any compensation for their participation in the study.

Code availability
Not applicable.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Consent for publication
All authors have participated in drafting, reviewing, and/or revising the manuscript and have approved its publication.

Competing interests
The authors declare no competing interests.

Author details
1 Dermatology Department, Pontevedra University Hospital, Simón Bolívar s/n, 36003 Pontevedra, Spain. 2 Medical Oncology Department, A Coruña University Hospital, Coruña, Spain. 3 Medical Oncology Department, Pontevedra University Hospital, Pontevedra, Spain. 4 Pharmacy Department, Pontevedra University Hospital, Pontevedra, Spain. 5 Surgical Medical Specialties Department, Dermatology Section, Santiago de Compostela University, Santiago, Spain.

Received: 24 November 2020 Accepted: 4 October 2021 Published online: 18 October 2021

References
1. Bottomley A, Reijneveld JC, Koller M, Flechtner H, Tomaszewski KA, Greimel E. 5th EORTC Quality of Life in Cancer Clinical Trials Conference Faculty. Current state of quality of life and patient-reported outcomes research. Eur J Cancer. 2019;121:53–63. https://doi.org/10.1016/j.ejca.2019.08.016.
2. Smith AB, Cocks K, Parry D, Taylor M. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G). Qual Life Res. 2014;23(3):971–6. https://doi.org/10.1007/s11136-013-0534-2.
3. Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JP, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Monpourn CM, Musoro JZ, O’Connor D, Oliver K, Pauult-Louis E, Piccart M, Pimentel FL, Quinlan C, Reijneveld JC, Schirmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C. Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clin Trials. 2018;15(6):624–30. https://doi.org/10.1177/1740774518795637.
4. Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67–73. https://doi.org/10.1200/edbk_159514.
5. Atkinson TM, Stover AM, Storfer DF, Saracino RM, D’Agostino TA, Pergoli D, Matsoukas K, Li Y, Basch E. Patient-reported physical function measures in Cancer Clinical Trials: Epidemiol Rev. 2017;39(1):59–70. https://doi.org/10.1093/epirev/mxx008.
6. Mooney K, Berry DL, Wiesenant M, Sjoberg D (2017) Improving Cancer Care Through the Patient Experience: How to Use Patient-Reported Outcomes in Clinical Practice. Am Soc Clin Oncol Educ Book. 2017;37:695–704. in Cancer Clinical Trials. Epidemiol Rev;39(1):59–70. https://doi.org/10.1200/edbk_175418.
7. Colombo R, Doherty DJ, Wilson CM, Krzyys K, Lange S, Maynes H (2018) Implementation and preliminary analysis of FACT-G Quality of Life Questionnaire within an Oncology Survivorship Clinic. Cureus;10(3):e2272. https://doi.org/10.7759/cureus.e2272.
8. Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, Hackl NA, Heading G. Choosing between the EORTC QLC-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011;22(10):2179–90. https://doi.org/10.1093/annonc/mdq271.
9. Wagner LL, Berg SR, Gandhi M, Hulbucky FJ, Webster K, Aneja M, Cella D, Lacouture ME. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFR)-18.
Support Care Cancer. 2013;21(4):1033–41. https://doi.org/10.1007/s00520-012-1623-4.

10. Dapueto JJ, Francolino C, Servente L, Chang CH, Gotta I, Levin R, Abreu Mdel C. Evaluation of the Functional Assessment of Cancer Therapy-General (FACT-G) Spanish Version-4 in South America: classic, psychometric and item response theory analyses. Health Qual Life Outcomes. 2003;20:1–32. https://doi.org/10.1186/1477-7525-1-32.

11. Sánchez R, Ballesteros M, Arnold BJ. Validation of the FACT-G scale for evaluating quality of life in cancer patients in Colombia. Qual Life Res. 2011;20:19–29. https://doi.org/10.1007/s11136-010-9727-0.

12. Young J, Badger-Parker T, Dobbins T, Jorgensen M, Gibbs P, Faragher I, Jones I, Cunow D. Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. J Pain Symptom Manag. 2015;49(2):258–64. https://doi.org/10.1016/j.jpainsymman.2014.06.006.

13. Keohane SG, Proby CM, Newlands C, Motley RJ, Nasr I, MohdMustapa MF, British Association of Dermatologists (Squamous and Basal Cell Carcinoma Guideline Development Groups), Slater DN, Royal College of Pathologists (Skin Cancer Lead). The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists. UK. Br J Dermatol. 2018;179(4):824–828.

14. U.S. Department of Health and Human Services (HHS), National Institutes of Health, National Cancer Institute (2020). Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. Accessed February 24, 2020, at https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.

15. Abu Sharour L, Malak M, Subih M, Bani Salameh A. Quality of life, care needs, and information needs among patients diagnosed with cancer during their treatment phase. Psychol Health Med. 2020;25(2):252–8. https://doi.org/10.1080/13548506.2019.1699660.

16. Jacob J, Palat G, Verghese N, Kumari P, Rapelli V, Kumari S, et al. Health-related quality of life and its socio-economic and cultural predictors among advanced cancer patients: evidence from the APPROACH cross-sectional survey in Hyderabad-India. BMC Palliat Care. 2019;18(1):94. https://doi.org/10.1186/s12904-019-0465-y.

17. Rosen AC, Case EC, Dzuza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–33. https://doi.org/10.1007/s12304-019-0465-5.

18. Huggins RH, Kuzel TM, Anderson RT, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–33. https://doi.org/10.1007/s12304-019-0465-5.

19. Huggins RH, Kuzel TM, Anderson RT, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–33. https://doi.org/10.1007/s12304-019-0465-5.

20. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park). 2007;21(11 (Suppl 5)):34–6.

21. Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol. 2016;13(5):319–25. https://doi.org/10.1038/nrclinonc.2015.222.

22. Gravalos C, Sanmartin O, Guiprude A, Espana A, Majem M, Suh Oh HJ, et al. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2019;21(5):556–71. https://doi.org/10.1007/s12094-018-1953-x.

23. Piper BF, Cella D. Cancer-related fatigue: definitions and clinical subtypes. J Natl Compr Canc Netw. 2010;8(8):958–66. https://doi.org/10.6004/jnccn.2010.0070.

24. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4–10. https://doi.org/10.1634/theoncologist.12-s1-4.

25. Clabbers JM, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJ, et al. Xerostomia and pruritus as major EGFR-associated adverse events. Support Care Cancer. 2016;24(2):513–21. https://doi.org/10.1007/s00520-015-2781-y.

26. Janusch M, Fischer M, Marsch W, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndrome—A frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol. 2006;16(5):494–9.

27. Urakawa R, Tarutani M, Kubota K, Uejima E. Hand foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy. J Cancer. 2019;10(20):4846–51. https://doi.org/10.7150/jca.31059.

28. Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, et al. Assessment of Quality of Life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724–8. https://doi.org/10.1001/jamadermatol.2019.5071.

29. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9. https://doi.org/1.1000/jco.1993.11.3.570.

30. Ediando D, Yaznil MR, Chartysnari AA, Efferdi H. Assessment of the Quality of Life for Gynecologic Cancer Patients Using Functional Assessment of Cancer Therapy-General (Fact-G) Questionnaire at Haji Adam Malik Hospital. Open Access Maced J Med Sci. 2017;16(1):2569–73. https://doi.org/10.3889/oamjms.2019.391.

31. Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, et al. The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study. Cancer Res Treat. 2018;50(4):1186–93. https://doi.org/10.4143/crt.2017.435.

32. Barbui MA, Nitisip C, Vouia T, Guiccanecou A. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study. Rom J Intern Med. 2018;56(2):96–101. https://doi.org/10.2478/rjim-2018-0002.

33. Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F, et al. Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes. 2010;8:40. https://doi.org/10.1186/1477-7525-8-40.

34. Nakao M, Fricchione G, Zuttermeister PC, Myers P, Barsky AJ, Benson H. Effects of gender and marital status on somatic symptoms of patients attending a mind/body medicine clinic. Behav Med. 2001;26(4):159–68. https://doi.org/10.1016/s0277-9536(98)00029-5.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.